Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast®: w/e 16 April 2021

Pearce IP BioBlast®: w/e 16 April 2021

13 April 2021 | Purple Biotech announced it presented further preclinical data supporting the mechanism of action of NT219 at the American Association of Cancer Research 2021 Annual Meeting. NT219 is being developed as a treatment for recurrent and/or metastatic solid...
Pearce IP BioBlast®: w/e 16 April 2021

Pearce IP BioBlast®: w/e 09 April 2021

06 April 2021 | PlantForm announced it has reached a collaborative research and development agreement with Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab for the Brazilian market. 06 April 2021 | US | The FDA approved a new dosage regimen for Erbitux®...
Pearce IP BioBlast®: w/e 16 April 2021

Pearce IP BioBlast®: w/e 02 April 2021

29 March 2021 | Samsung Bioepis announced on 29 March 2021 that it has launched Hadlima®, its 50mg/mL biosimilar adalimumab in Australia and Canada. Australia’s PBAC previously confirmed that Hadlima® would be PBS listed from 01 April 2021. 30 March 2021 | STADA...
Pearce IP BioBlast®: w/e 16 April 2021

Pearce IP BioBlast®: w/e 26 March 2021

24 March 2021 | EirGenix announced that its Ph III clinical trial of EG12014 (proposed trastuzumab biosimilar) has met its primary endpoint. EirGenix announced that EG12014 has shown equivalent efficacy to Herceptin®, and demonstrated a comparable safety profile. 25...
Pearce IP BioBlast®: w/e 16 April 2021

Pearce IP BioBlast®: w/e 19 March 2021

15 March 2021 | Alvotech announced it has completed a second round of its US$100 million private placement.  In the first round, Alvotech raised US$65 million, including investments from Korea’s Shinhan, US’ Baxter Healthcare SA, and Germany’s ATHOS....